Posted by Michael Wonder on 08 Mar 2022
NICE yet to support the use of pralsetinib on the NHS
3 March 2022 - NICE publishes appraisal consultation document for a new medicine for certain patients with non-small-cell lung cancer.
Pralsetinib (Gavreto) is not recommended, within its marketing authorisation, for treating RET fusion positive advanced non-small-cell lung cancer in adults who have not had a RET inhibitor before.
